Company intelligence / Profile preview

Transcept Pharmaceuticals

King Of Prussia, Pennsylvania, USAprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

Transcept Pharmaceuticals developed proprietary products in neuroscience, most notably Intermezzo (zolpidem tartrate sublingual tablet), which received FDA approval in 2011 for insomnia characterized by middle-of-the-night awakenings. The company licensed U.S. commercialization rights for Intermezzo to Purdue Pharma and was later acquired by Paratek Pharmaceuticals in 2014.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

zolpidem tartrate

Commercial

Indications: Insomnia

Partnerships

Purdue Pharma – exclusive U.S. licensee for commercialization of Intermezzo

Beyond the preview

Go deeper on Transcept Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcept Pharmaceuticals.

Explore the full profile